A comparison of the central effects of different progestins used in hormone replacement therapy

Maturitas

Volumn 48, Issue 4, 2004, Pages 456-462

  Cagnacci, Angelo ^a   Arangino, Serenella ^a   Baldassari, Francesco ^a   Alessandrini, Chiara ^a   Landi, Stefano ^a   Volpe, Annibale ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Anxiety; Body temperature; Depression; Menopause; Mood; Progestins; Psychological symptoms

Indexed keywords

DYDROGESTERONE; ESTRADIOL; GESTAGEN; MEDROXYPROGESTERONE ACETATE; NOMEGESTROL ACETATE; NORETHISTERONE ACETATE; PLACEBO;

ADULT; ANXIETY; ARTICLE; BASAL BODY TEMPERATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SELF EVALUATION; STATISTICAL SIGNIFICANCE;

ADMINISTRATION, CUTANEOUS; ANXIETY; BODY TEMPERATURE; DEPRESSION; DOUBLE-BLIND METHOD; ESTRADIOL; FEMALE; FOLLOW-UP STUDIES; HORMONE REPLACEMENT THERAPY; HOT FLASHES; HUMANS; MEDROXYPROGESTERONE; MEDROXYPROGESTERONE 17-ACETATE; MEGESTROL; MIDDLE AGED; NORETHINDRONE; NORPREGNADIENES; PLACEBOS; POSTMENOPAUSE; PROGESTINS; TIME FACTORS;

NETA;

EID: 3342936425     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2003.10.003     Document Type: Article

References (30)

1. Cagnacci A., Melis G.B., Soldani R., Paoletti A.M., Fioretti P. Effect of sex steroids on body temperature in postmenopausal women. Role of endogenous opioids. Life Sci. 50:1992;515-521
2. Cagnacci A., Elliott J.A., Yen S.S.C. Modification of circadian body temperature rhythm during the luteal menstrual phase: role of melatonin. J. Appl. Physiol. 80:1996;25-29
3. Prior J.C., Alojado N., McKay D.W., Vigna Y.M. No adverse effects of medroxy-progesterone treatment without estrogen in postmenopausal women: double-blind, placebo-controlled, cross-over trial. Obstet. Gynecol. 83:1994;24-28
4. Pearlstein T.B. Hormones and depression: what are the facts about premenstrual syndrome, menopause, and hormone replacement therapy? Am J. Obstet. Gynecol. 173:1995;646-653
5. Sherwin B.B. The impact of different doses of estrogen and progestin on mood and sexual behavior in postmenopausal women. J. Clin. Endocrinol. Metab. 72:1991;336-343
6. Zweifel J.E., O'Brien W.H. A meta-analysis of the effect of hormone replacement therapy upon depressed mood. Psychoneuroendocrinology. 22:1997;189-212
7. Scmidt P.J., Nieman L.K., Danaceau M.A., Adams L.F., Rubinow D.R. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N. Engl. J. Med. 338:1998;209-216
8. Siddle N.C., Fraser D., Whitehead M.I., Jesinger D.K., Endacott J., Prescott P., et al. Endometrial, physical and psychological effects of postmenopausal oestrogen therapy with added dydrogesterone. Br. J. Obst. Gynaecol. 97:1990;1101-1107
9. Hammarback S., Bacstrom T., Holst J., von Schoultz B., Lyrenas S. Cyclical mood changes as in the premenstrual syndrome during sequential estrogen-progestagen postmenopausal replacement therapy. Acta Obstet. Gynecol. Scand. 64:1985;393-397
10. Magos A.L., Brewster E., Singh R., O'Dowd T., Brincat M., Studd J.W.W. The effect of norethisterone in postmenopausal women on estrogen replacement therapy: a model for the premenstrual syndrome. Br. J. Obstet. Gynaecol. 93:1986;1290-1296
11. Kirkham C., Hahn P.M., Van Vugt D.A., Carmichael J.A., Reid R.L. A randomized, double-blind, placebo-controlled, cross-over trial to assess the side effects of medroxyprogesterone acetate in hormone replacement therapy. Obstet. Gynecol. 78:1991;93-97
12. Greendale G.A., Reboussin B.A., Hogan P., et al. For the postmenopausal estrogen/progestin interventions trial investigators. Symptom relief and side effects of postmenopausal hormones: results from the postmenopausal estrogen/progestin intervention trial. Obstet. Gynecol. 92:1998;982-988
13. Natale V., Albertazzi P., Zini M., Di Micco R. Exploration of cyclical changes in memory and mood in postmenopausal women taking sequential combined oestrogen and progestogen preparations. BJOG. 108:2001;286-290
14. Girdler S.S., O'Briant C., Steege J., Grewen K., Light K.C. A comparison of the effect of estrogen with or without progesterone on mood and physical symptoms in postmenopausal women. J. Womens Health Gender Based Med. 8:1999;637-646
15. Editorial. Progestins: present and future. J Steroid Biochem Molec Biol 1996;59:357-63.
16. Stanczyk FZ. Structure-function relationships, potency, and pharmacokinetics of progestogens. In: Lobo RA, editor. Treatment of the postmenopausal woman: basic and clinical aspects. New York: Raven Press; 1994. p. 69-89.
17. Cagnacci A., Volpe A., Arangino S., Mamlmusi S., Draetta F.P., Matteo M.L., et al. Depression and anxiety in climacteric women: role of hormone replacement therapy. Menopause. 4:1997;206-211
18. McCarthy T., Dramusic V., Carter R., Costales A., Ratnam S.S. Randomized cross-over study of a 21-day versus 28-day hormone replacement therapy (HRT). Maturitas. 22:1995;13-23
19. Saadat P., Boostanfar R., Poysky J., Munevar C.M., Stanczyk F.Z., Buckwalter G., et al. A randomized prospective study comparing the effects of micronized progesterone and medroxyprogesterone acetate on mood and libido. Fertil. Steril. 77(Suppl 3):2002;s21
20. Bjorn I., Bixio M., Nojd K.S., Nyberg S., Backstrom T. Negative mood changes during hormone replacement therapy: a comparison between two progestogens. Am. J. Obstet. Gynecol. 183:2000;1419-1426
21. Cummings J.A., Brizendine L. Comparison of physical and emotional side effects of progesterone or medroxyprogesterone in early postmenopausal women. Menopause. 9:2002;253-263
22. Spielberg CD, Gorsuch RL, Lusehene RE, Manual for the state-trait anxiety inventory (self-evaluation questionnaire). Palo Alto, CA: Consulting Psychologists Press; 1970.
23. Zung W.W.K. A self-rating depression scale. Arch. Gen. Psych. 12:1965;63-70
24. Cagnacci A., Melis G.B., Soldani R., Paoletti A.M., Gambacciani M., Spinetti A., et al. Neuroendocrine and clinical effects of transdermal 17 β-estradiol in postmenopausal women. Maturitas. 13:1991;283-296
25. Sitruk-Ware R. Progestogens in hormonal replacement therapy: new molecules, risks, and benefits. Menopause. 9:2002;6-15
26. van Amsterdam P.H., Overmars H., Scherpenisse P.M., de Bree H., Post L.C. Dydrogesterone: metabolism in man. Eur. J. Drug. Metab. Pharmacok. 5:1980;173-184
27. Bjorn I., Bixio M., Nojd K.S., Collberg P., Nyberg S., Sundstrom-Poromaa I., et al. The impact of different doses of medroxyprogesterone acetate on mood symptoms in sequential hormonal therapy. Gynecol. Endocrinol. 16:2002;1-8
28. Smith SS. Hormones, mood and neurobiology. A summary. In: Berg G, Hammar M, editors. The modern management of the menopause. A perspective for the 21st century. London: Parthenon Publishing Group; 1994, p. 257-68.
29. de Lignières B., Vincens M. Differential effects of exogenous estradiol and progesterone on mood in post-menopausal women: individual dose/effect relationship. Maturitas. 4:1982;67-72
30. Holst J., Backstrom T., Hammarback S. Progestogen addition during oestrogen replacement therapy. Effects on vasomotor symptoms and mood. Maturitas. 11:1989;13-20